Brief: Hcw Biologics Inc. Announces Its Lead Product Candidate Shown To Augment Anti-Tumor Activity And Reduce Side Effects Of Chemotherapy Regimens
20/01/2022 13:20
Jan 20 (Reuters) - HCW Biologics Inc HCWB.O :
* HCW BIOLOGICS INC. ANNOUNCES ITS LEAD PRODUCT CANDIDATE
SHOWN TO
AUGMENT ANTI-TUMOR ACTIVITY AND REDUCE SIDE EFFECTS OF
CHEMOTHERAPY REGIMENS
Source text for Eikon: ID:nGNXbc7kjZ
Further company coverage: HCWB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM